Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001356576-22-000004
Filing Date
2022-02-10
Accepted
2022-02-10 17:17:29
Documents
14
Period of Report
2022-02-10
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A supn-20220210.htm   iXBRL 8-K/A 66665
2 EX-23.1 ex23102-10x2022consentofpr.htm EX-23.1 2252
3 EX-99.4 ex99402-10x2022unauditedpr.htm EX-99.4 314553
  Complete submission text file 0001356576-22-000004.txt   548470

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT supn-20220210.xsd EX-101.SCH 1915
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT supn-20220210_lab.xml EX-101.LAB 24136
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT supn-20220210_pre.xml EX-101.PRE 12520
8 EXTRACTED XBRL INSTANCE DOCUMENT supn-20220210_htm.xml XML 10836
Mailing Address 9715 KEY WEST AVENUE ROCKVILLE MD 20850
Business Address 9715 KEY WEST AVENUE ROCKVILLE MD 20850 301-838-2500
SUPERNUS PHARMACEUTICALS, INC. (Filer) CIK: 0001356576 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-35518 | Film No.: 22615335
SIC: 2834 Pharmaceutical Preparations